Osiris to Present Advanced Research on Chronic Wound Treatment Using Its Viable Cryopreserved Placental Membrane

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, will present advanced research on cryopreserved cellular placental membranes and their use in treating chronic wounds at the Symposium on Advanced Wound Care (SAWC™), the nation’s largest interdisciplinary wound care event that works to improve wound care outcomes through education.

A total of twelve abstracts demonstrating the benefits of Osiris’ viable human amniotic membrane, Grafix®, will be presented.

The poster “Human Cryopreserved Viable Placental Membrane (hCVPM) Inhibits the Growth of Bacteria Associated with Chronic Wounds” (Abstract # LB-012), conducted by a third party academic lab, for the first time, showed that hCVPM inhibits the growth of bacteria species associated with chronic wounds. The study demonstrates that hCVPM inhibited the growth of all ESKAPE pathogens encompassing the six bacteria known for multidrug resistance and biofilm formation: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter aerogenes. hCVPM had an effect on both gram positive and negative bacteria. There was an average 4 to 6 Log bacterial growth reduction observed.

The poster “Understanding Placental Products: Impact of Commercial Preservation Methods on Tissue Integrity and Anti-Inflammatory and Angiogenic Properties” (Abstract # LB-002) compared the properties of human placental membranes processed by three commercial preservation methods: BioSmart™, CryoTek® and Purion® and showed that the BioSmart processing method retains the placental membrane in its native state with the highest anti-inflammatory and angiogenic activity. BioSmart, contrary to dehydration, is the only manufacturing technology that preserves the native components found in placental membranes, including endogenous cells, growth factors and 3-D structural matrix.

Clinical specialists will present 10 new abstracts describing the successful use of Grafix in some of the most challenging wounds encountered in “real-life” wound care practice. Case series presented will include patients with chronic non-healing wounds and significant compromise to their lower limb blood flow, patients who continue to smoke while receiving treatment, patients with wounds that have failed to respond to other advanced wound care therapies, and patients with large, complex, non-healing wounds. The full list of abstracts is as follows:

  • “Evaluating the Impact of a Viable Intact Cryopreserved Human Amniotic Membrane on Percent Area Reduction in Recalcitrant Wound Outliers after Multiple Advanced Treatment Failures” (Abstract # CS-105)
  • “Challenging Lower Limb Ulcerations in Patients with Impaired Tissue Perfusion: Application of a Viable Intact Cryopreserved Human Amniotic Membrane to Achieve Wound Closure” (Abstract # CS-099)
  • “Accelerating Closure of a Complex Sternal Wound in an Elderly Diabetic Patient with Multiple Risk Factors for Treatment Failure Utilizing a Viable Intact Cryopreserved Human Amniotic Membrane” (Abstract # CS-008)
  • “Retrospective Review of Multipotent Mesenchymal Stem Cell Matrix For Burn Wound Closure” (Abstract # CS-020)
  • “Expedient Wound Closure Utilizing Viable Placental Tissue in Serious Limb Threatening Infection: A Case Study” (Abstract # CS-044)
  • “Utilization of Cellular Human Repair Matrix with Concomitant Mechanically Powered Negative Pressure Wound Therapy for Accelerated Healing of Various Chronic Diabetic Foot Ulcers” (Abstract # CS-104)
  • “Treatment of Challenging Lower Extremity Wounds with Bone and Tendon Exposure: Using a Uniquely Viable and Intact Cryopreserved Human Placental Membrane Graft for Closure” (Abstract # CS-102)
  • “A Case Study of Five Diabetic Foot Ulcerations Treated with a Human Cellular Repair Matrix to Accelerate Wound Closure” (Abstract # CS-038)
  • “Wound Closure of Chronic Foot Ulcers using Cryopreserved Human Amniotic Membrane” (Abstract # CS-027)
  • “The Use of Cryopreserved Human Amniotic Membrane in the Closure of Chronic Wounds” (Abstract # CS-066)

Osiris Therapeutics will also be exhibiting at the Symposium on Advanced Wound Care meeting at booth 421. The event runs from September 26 through September 28, 2015 at Caesars Palace in Las Vegas, Nevada.

About Osiris Therapeutics

Osiris Therapeutics, Inc., based in Columbia, Maryland, is the world leader in researching, developing and marketing regenerative medicine products that improve health and lives of patients and lower overall healthcare costs. Having developed the world’s first approved stem cell drug, the company continues to advance its research and development in biotechnology by focusing on innovation in regenerative medicine – including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in orthopaedics, sports medicine and wound care, including BIO4™, Cartiform® and Grafix.

Osiris, Grafix, and Cartiform are registered trademarks of Osiris Therapeutics, Inc. BIO4 is a trademark of Stryker Corporation (NYSE: SYK). All other trademarks belong to their respective owners. More information can be found on the company's website, www.Osiris.com. (OSIR-G)

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as "anticipate," "believe," "continue," "ongoing," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project" or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements may include, without limitation, statements regarding any of the following: our product development efforts; our clinical trials and anticipated regulatory requirements, and our ability to successfully navigate these requirements; the success of our product candidates in development; status of the regulatory process for our biologic drug candidates; implementation of our corporate strategy; our financial performance; our product research and development activities and projected expenditures, including our anticipated timeline and clinical strategy biologic drug candidates and marketed Biosurgery products (including Grafix, BIO4 and Cartiform); our cash needs; patents, trademarks and other proprietary rights; the safety and ability of our products and potential products to treat disease; our ability to supply a sufficient amount of our marketed products or product candidates and, if approved or otherwise commercially available, products to meet demand; our costs to comply with governmental regulations; our plans for sales and marketing; our plans regarding facilities; types of regulatory frameworks we expect will be applicable to our products and potential products; and results of our scientific research. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Our actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in the section entitled "Risk Factors" in our Annual Report on Form 10-K and other Periodic Reports filed on Form 10-Q, with the United States Securities and Exchange Commission. Accordingly, you should not unduly rely on these forward-looking statements. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events.

Contacts:

Osiris Therapeutics, Inc.
Amanda Badillo, 443-545-1834
OsirisPR@Osiris.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.